Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
5/29/2026, 12:00:00 AM
Received FDA Breakthrough Therapy designation for calderasib (MK-1084) on May 29, 2026. Medium importance as this designation accelerates the development of a key oncology candidate.
Korean Translation
2026년 5월 29일 비소세포폐암(NSCLC) 환자의 1차 치료를 위한 칼데라십(MK-1084)에 대해 FDA로부터 혁신 치료제 지정을 승인받음.
Related Recent Events
Life Time Group Holdings Inc (LTH) · Earnings Release
Q2 2026 earnings release on 2026-08-04 with analyst EPS forecast of $0.43; low importance estimated due to no current market impact, expected.
8/4/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
Second quarter 2026 financial results for 2026-07-21; low importance estimated as the date is a routine reporting event with an expected impact of approximately 1% scheduled.
7/21/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
6/19/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
Quarterly dividend of $0.85 per share has an ex-dividend date of June 15, 2026, scheduled.
6/15/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Ex-dividend date for a quarterly cash dividend of $1.25 per share on 2026-06-12. The dividend was declared on May 26, 2026, and is payable on June 26, 2026. A price impact of approximately 1% is expected based on the dividend amount.
6/12/2026, 12:00:00 AM